FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834

Thrombosis Research

Volumn 103, Issue 4, 2001, Pages 281-297

  McLean, K ^a   Schirm, S ^a   Johns, A ^a   Morser, J ^a   Light, D R ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; BLOCKING ANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BRADYKININ; CALCIUM ION; CELL RECEPTOR; DNA; EFFECTOR CELL PROTEASE 1 RECEPTOR; EGTAZIC ACID; HIRUDIN; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ATAP2; MONOCLONAL ANTIBODY WEDE15; N [2 (5 AMIDINO 2 HYDROXYPHENOXY) 3,5 DIFLUORO 6 [3 (1 METHYL 1H 2 IMIDAZOLIN 2 YL)PHENOXY] 4 PYRIDINYL] N METHYLGLYCINE; N [2 [5 [AMINO(IMINO)METHYL] 2 HYDROXYPHENOXY] 3,5 DIFLUORO 6 [3 (4,5 DIHYDRO 1 METHYL 1H IMIDAZOL 2 YL)PHENOXY]PYRIDIN 4 YL] N METHYLGLYCINE; OSTEOCALCIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTHROMBIN; THROMBIN; THROMBOPLASTIN; THYMIDINE; UNCLASSIFIED DRUG;

ARTERY ENDOTHELIUM; ARTERY MUSCLE; ARTERY WALL; ARTICLE; BLOOD VESSEL WALL; CALCIUM CELL LEVEL; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

AMIDINES; CALCIUM SIGNALING; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FACTOR V; FACTOR XA; HUMANS; PYRIDINES; RECEPTOR, PAR-1; RECEPTOR, PAR-2; RECEPTORS, CELL SURFACE; RECEPTORS, THROMBIN; SERINE PROTEINASE INHIBITORS; SIGNAL TRANSDUCTION; THROMBIN;

EID: 0035881168     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00330-9     Document Type: Article

References (73)

1. Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leukocyte initiation of coagulation
2. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa
3. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits
4. Prolonged activation of prothrombin on the vascular wall after arterial injury
5. Pathogenesis of thrombosis in coronary artery disease
6. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes
7. Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries
8. The role of secondary growth factor production in thrombin-induced proliferation of vascular smooth muscle cells
9. Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism
10. 2+ oscillations induced in Madin Darby canine kidney cells by bradykinin and thrombin but not by ATP
11. Thrombin is an extracellular signal that activates intracellular death protease pathways inducing apoptosis in model motor neurons
12. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
13. The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a Par gene cluster and characterization in vascular endothelial cells and platelets
14. Protease-activated receptors and their role in IL-6 and NF-IL-6 expression in human gingival fibroblasts
15. Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation
16. Functional thrombin receptors on human T lyphoblastoid cells
17. Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons
18. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis
19. Protease activated receptor 3 is a second thrombin receptor in humans
20. Cloning and characterization of human protease-activated receptor 4
21. Evidence for proteinase-activated receptor-2 (PAR-2)-mediated mitogenesis in coronary artery smooth muscle cells
22. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1
23. PAR3 is a cofactor for PAR4 activation by thrombin
24. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells
25. Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling
26. Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo
27. Protease-dependent T cell activation: Ligation of effector cell protease receptor-1 (EPR-1) stimulates lymphocyte proliferation
28. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa
29. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
30. Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1
31. Factor Xa activates endothelial cells by a receptor cascade between EPR-1 and PAR-2
32. The elusive factor Xa receptor: Failure to detect transcripts that correspond to the published sequence of EPR-1
33. Discovery of N-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5- dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834): A potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa
34. Structure and function of the human platelet thrombin receptor
35. Contribution of the prothrombin fragment 2 domain to the function of factor Va in the prothrombinase complex
36. Proteinase-activated receptor 2 (PAR(2)): Development of a ligand-binding assay correlating with activation of PAR(2) by PAR(1)- and PAR(2)-derived peptide ligands
37. Mechanisms of initiation and termination of signalling by neuropeptide receptors: A comparison with the proteinase-activated receptors
38. Ligand cross-reactivity within the protease-activated receptor family
39. Identification of effector cell protease receptor-1
40. Effector cell protease receptor-1, a platelet activation dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation
41. Activation dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease-1
42. Molecular dissection of effector cell protease receptor-1 recognition of factor Xa
43. The contribution of bovine factor V and factor Va to the activity of prothrombinase
44. Activation of human vascular endothelial cells by factor Xa: Effect of specific inhibitors
45. Detection of factor X activation in humans
46. Analysis of the functions of the first epidermal growth factor-like domain of factor X
47. 2+ binding site yet retains function
48. Role of proexosite I in factor Va-dependent substrate interactions of prothrombin activation
49. Characterization of proexosite I on prothrombin
50. Proteinase-activated receptor-2: Expression by human neutrophils
51. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
52. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2
53. Induction of vascular smooth muscle cell growth by selective activation of the proteinase activated receptor-2 (PAR-2)
54. Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo
55. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw
56. Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling
57. Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo
58. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin
59. Thrombin functions as an inflammatory mediator through activation of its receptor
60. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events
61. Elevated levels of interleukin-6 in unstable angina
62. Inflammatory profile in unstable angina versus stable angina in patients undergoing percutaneous interventions
63. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage
64. Evidence that thrombin mediates secondary fibrinolysis in disseminated intravascular coagulation
65. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody
66. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli
67. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
68. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits
69. RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit
70. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis
71. Coronary artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty
72. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
73. Effects of ZK-807834, A novel antagonists of factor Xa, on thrombosis progression in rabbits